Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.30)
# 2,476
Out of 4,479 analysts
53
Total ratings
38%
Success rate
-15.56%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $5.72 | - | 3 | May 29, 2024 | |
| ASND Ascendis Pharma | Reiterates: Overweight | $173 | $136.27 | +26.95% | 10 | May 15, 2024 | |
| CRIS Curis | Reiterates: Overweight | n/a | $6.25 | - | 1 | May 15, 2024 | |
| VINC Vincerx Pharma | Reiterates: Overweight | n/a | $0.74 | - | 5 | Apr 9, 2024 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Overweight | n/a | $1.78 | - | 3 | Apr 1, 2024 | |
| AFMD Affimed | Reiterates: Overweight | n/a | $5.16 | - | 5 | Apr 1, 2024 | |
| SLS SELLAS Life Sciences Group | Reiterates: Overweight | $3 | $1.12 | +167.86% | 3 | Nov 22, 2023 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $46 → $36 | $14.65 | +145.73% | 1 | Nov 8, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Overweight | $65 | $19.81 | +228.12% | 4 | Nov 8, 2023 | |
| PRTG Portage Biotech | Reiterates: Overweight | $11 | $0.18 | +6,182.12% | 3 | Sep 7, 2023 | |
| ONCT Oncternal Therapeutics | Reiterates: Neutral | $26 | $7.05 | +268.79% | 3 | Sep 7, 2023 | |
| KURA Kura Oncology | Reiterates: Overweight | $30 | $20.58 | +45.77% | 4 | Sep 7, 2023 | |
| FATE Fate Therapeutics | Reiterates: Neutral | $5 | $3.22 | +55.28% | 3 | Sep 7, 2023 | |
| ARVN Arvinas | Reiterates: Overweight | $70 | $24.85 | +181.69% | 2 | Sep 7, 2023 | |
| APTO Aptose Biosciences | Reiterates: Overweight | $38 | $0.74 | +5,014.40% | 2 | Sep 7, 2023 | |
| NKTX Nkarta | Maintains: Overweight | $60 → $38 | $5.26 | +622.43% | 1 | Aug 12, 2022 |
ALX Oncology Holdings
May 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.72
Upside: -
Ascendis Pharma
May 15, 2024
Reiterates: Overweight
Price Target: $173
Current: $136.27
Upside: +26.95%
Curis
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.25
Upside: -
Vincerx Pharma
Apr 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.74
Upside: -
Corvus Pharmaceuticals
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.78
Upside: -
Affimed
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.16
Upside: -
SELLAS Life Sciences Group
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.12
Upside: +167.86%
Arcus Biosciences
Nov 8, 2023
Maintains: Overweight
Price Target: $46 → $36
Current: $14.65
Upside: +145.73%
Bicycle Therapeutics
Nov 8, 2023
Reiterates: Overweight
Price Target: $65
Current: $19.81
Upside: +228.12%
Portage Biotech
Sep 7, 2023
Reiterates: Overweight
Price Target: $11
Current: $0.18
Upside: +6,182.12%
Oncternal Therapeutics
Sep 7, 2023
Reiterates: Neutral
Price Target: $26
Current: $7.05
Upside: +268.79%
Kura Oncology
Sep 7, 2023
Reiterates: Overweight
Price Target: $30
Current: $20.58
Upside: +45.77%
Fate Therapeutics
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $3.22
Upside: +55.28%
Arvinas
Sep 7, 2023
Reiterates: Overweight
Price Target: $70
Current: $24.85
Upside: +181.69%
Aptose Biosciences
Sep 7, 2023
Reiterates: Overweight
Price Target: $38
Current: $0.74
Upside: +5,014.40%
Nkarta
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $5.26
Upside: +622.43%